European Journal of Cancer
Volume 37, Issue 3 , Pages 347-354 , February 2001

c-erbB-2 Positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease

  • A Jukkola

      Affiliations

    • Department of Oncology, University of Oulu, Finland
    • ,
  • R Bloigu

      Affiliations

    • Department of Medical Informatics, University of Oulu, Finland
    • ,
  • Y Soini

      Affiliations

    • Department of Pathology, University of Oulu, Finland
    • ,
  • E.-R Savolainen

      Affiliations

    • Department of Clinical Chemistry, University of Oulu, Finland
    • ,
  • K Holli

      Affiliations

    • Department of Oncology, University of Tampere, Finland
    • ,
  • G Blanco

      Affiliations

    • Department of Oncology, University of Oulu, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +358-8-3152011; fax: +358-8-3153229

Received 10 April 2000 ,Revised 11 September 2000 ,Accepted 2 November 2000.

References 

  1. Coussens L, Yang-Feng TL, Laian YC, et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132–1149
  2. Borg A, Baldetorp B, Ferno' M, Killander D, Olson H, Sifurdsson H. ERBB2 amplification in breast cancer with high rate of proliferation. Oncogene. 1991;6:137–143
  3. Kraus MH, Popescu NC, Amsbaugh SC, King R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987;6:605–610
  4. Di Fiore PP, Pierce JH, Kraus MH, Oreste S, King CR, Aaronson A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987;237:127–182
  5. Paterson MC, Dietrich KD, Danyluk J, et al.  Correlation of c-erbB-2 amplification and risk of recurrence disease in node negative breast cancer. Cancer Res. 1991;51:556–567
  6. Berger MS, Locher GW, Saurer S, et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988;48:1238–1243
  7. O'Relly SM, Barnes DM, Camplejohn RS, Bartkowa J, Gregory WM, Richards MA. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br. J. Cancer. 1991;63:444–446
  8. Thor AD, Berry DA, Budman DR, et al.  erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. National Cancer Institute. 1998;90:1346–1360
  9. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin H, Isola J. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastases and poor long-term survival in breast cancer. Int. J. Cancer. 1991;49:650–655
  10. Leitzel K, Teramoto Y, Konrad K, et al.  Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 1995;13:1129–1135
  11. Yamauchi H, O'Neil A, Gelman R, et al.  Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol. 1997;15:2518–2525
  12. Carlomagno C, Perrone F, Gallo C, et al.  HER2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without axillary node metastases. J. Clin. Oncol. 1996;14:2702–2708
  13. Gusterson BA, Gellber RD, Goldhirch A, et al.  Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol. 1992;10:1049–1056
  14. Allred DC, Clark GM, Tandon AK, et al.  Her-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol. 1992;10:599–605
  15. Narita M, Nakao K, Ogino NK, Nakahara M, Onishi A, Tsujumoto M. Independent prognostic factor in breast cancer patients. Am. J. Surg. 1998;175:73–75
  16. Rozan S, Vincent-Salomon A, Zafrani B, et al.  No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer. 1998;79:27–33
  17. Muss HB, Thor AD, Berry DA, et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 1994;330:1260–1266
  18. Paik S, Bryant J, Park C, et al.  erb-B2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl Cancer Inst. 1998;90:1361–1370
  19. Elston CW, Ellis IO. Pathologic prognostic factors. The value of histological grade in breast cancer (experience from a large study with long-term follow-up). Histopathology. 1991;19:403–410
  20. Frye RA, Benz CC, Liu E. Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene. 1989;4:1153–1157
  21. Bargmann CI, Hung M-C, Weinberg RA. The NEU oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986;119:226–230
  22. Marx D, Schauer A, Reiche C, et al.  c-erbB-2 expression in correlation to other biological parameters of breast cancer. J. Cancer Res. Clin. Oncol. 1990;116:15–20
  23. Tsuda H, Hirohashi S, Shimosato Y, et al.  Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer. 1990;65:1794–1800
  24. Slamon DJ, Godolphin W, Jones LA, et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  25. Archer SG, Eliopoulos A, Spandidos D, et al.  Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer. 1995;72:1259–1266
  26. Elledge R, Green S, Ciocca D, et al.  HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A southwest oncology group study. Clin. Cancer Res. 1998;4:7–12
  27. Pietras RJ, Arboleda J, Reese DM, et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-indepedent growth in human breast cancer cells. Oncogene. 1995;10:2435–2446
  28. Järvinen TA, Kononen J, Pelto-Huikko M, Isola J. Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy and c-erbB2 overexpression in breast cancer. Am. J. Pathol. 1996;148:2073–2082
  29. Harris AL, Carmichael J. Topoisomerase inhibitors and multiple drug resistance mechanism in human breast cancer. In:  Dickson RB,  Lippman ME editor. Drug and Hormonal Resistance in Breast Cancer. New York: Ellis Horwood; 1995;p. 303–322

PII: S0959-8049(00)00395-6

European Journal of Cancer
Volume 37, Issue 3 , Pages 347-354 , February 2001

Article Tools

* Image Usage & Resolution